PRTA 241220 15.00P (PRTA241220P15000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

PRTA241220P15000

Watchlist

0.27
-0.13-32.50%

15min DelayClose Dec 20 16:00 ET

0.75High0.27Low

Intraday

5D
Daily

News

H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $48
Moomoo NewsDec 21 07:32 ET · Ratings
Leerink Partners Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $40
Moomoo NewsDec 21 07:32 ET · Ratings
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
BenzingaDec 20 09:52 ET
Prothena Price Target Cut to $48.00/Share From $84.00 by HC Wainwright & Co.
Dow JonesDec 20 07:19 ET · Ratings
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
BenzingaDec 20 07:01 ET · Ratings
Prothena Stock Gains 38% After Parkinson's Treatment Shows Potential Benefits
WSJDec 19 15:29 ET · Movers

Comments

Jaguar8

Dec 19 10:16

Missed primary endpoint but went up 😂

$Prothena (PRTA.US)$

Moomoo AI

Jan 31 05:38

Investors may miss opportunities or face setbacks if there's no rational basis for the P/S ratio. The moderate P/S ratio suggests investors anticipate a slowdown in revenue. Many investors, less bearish than analysts, hold onto their stocks, risking future disappointment if P/S aligns with growth outlook.

What Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Not Telling You

Moomoo AI

Nov 28, 2023 05:12

Analysts are forecasting that Prothena will reach break-even point before it might exhaust its cash runway. Given its impressive revenue growth and reduction in cash burn, Prothena appears well positioned to fund further growth with minimal shareholder dilution or borrowing.

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Moomoo AI

Oct 30, 2023 07:14

Despite recent declines, the company's strong growth signals a potential investment opportunity. Market response to its revenue growth indicates interest despite lack of profits.

Prothena (NASDAQ:PRTA) Shareholders Are Still up 224% Over 3 Years Despite Pulling Back 15% in the Past Week

Moomoo AI

Oct 9, 2023 08:34

Overvaluation risk looms for Prothena's shares with high P/S ratio amid poor revenue and weak growth forecast. Investors may face disappointment if the share price realigns with the firm's bleak future outlook.

Prothena Corporation Plc's (NASDAQ:PRTA) Price Is Out Of Tune With Revenues